

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Porcilis Lawsonia ID lyophilisate and solvent for emulsion for injection for pigs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 0.2 ml reconstituted vaccine contains:

Active substance (lyophilisate):

Inactivated *Lawsonia intracellularis* strain SPAH-08 ≥ 5323 U¹

¹ Antigenic mass units as determined in the *in vitro* potency test (ELISA).

Adjuvant (solvent):

Paraffin, light liquid 8.3 mg

DL- α -tocopheryl acetate 0.6 mg

Excipients:

Qualitative composition of excipients and other constituents
Lyophilisate:
Sodium chloride
Potassium chloride
Disodium phosphate dihydrate
Potassium dihydrogen phosphate
Water for injections
Solvent:
Polysorbate 80
Simeticone
Sodium chloride
Potassium chloride
Disodium phosphate dihydrate
Potassium dihydrogen phosphate
Water for injections

Lyophilisate: white/nearly white pellet/powder.

Solvent: homogenous white to nearly white emulsion after shaking.

3. CLINICAL INFORMATION

3.1 Target species

Pigs.

3.2 Indications for use for each target species

For the active immunisation of pigs from 3 weeks of age to reduce diarrhoea, loss of daily weight gain, intestinal lesions, bacterial shedding and mortality caused by *Lawsonia intracellularis* infection.

Onset of immunity: 4 weeks after vaccination.
Duration of immunity: 21 weeks after vaccination.

3.3 Contraindications

None.

3.4 Special warnings

Vaccinate healthy animals only.

This vaccine is intended for intradermal administration only.
The lyophilisate must be reconstituted in the dedicated “Solvent for Porcilis Lawsonia ID”, or in Porcilis PCV ID or in Porcilis PCV M Hyo ID following the instructions given in section 3.9.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Pigs:

Very common (>1 animal / 10 animals treated):	Elevated temperature ⁽¹⁾ , injection site swelling ⁽²⁾
--	--

⁽¹⁾ Mean increase 0.1°C, up to 1.4°C in individual pigs. The animals return to normal temperature within 1 day after vaccination.

⁽²⁾ Mean diameter of approximately 1cm, in individual pigs up to 5cm. Injection site swelling disappears within 4 weeks after vaccination.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Can be used during pregnancy and lactation. However, the vaccine is recommended for single use only (see section 3.9)..

3.8 Interaction with other medicinal products and other forms of interaction

Safety and efficacy data, except for protection against mortality, are available in pigs from 3 weeks of age onwards which demonstrate that this vaccine can be administered mixed with Porcilis PCV ID and/or non-mixed with Porcilis M Hyo ID ONCE and/or non-mixed with Porcilis PRRS (intradermal route) providing that administration sites of vaccines are separated by at least 3 cm.

Adverse events are as described in section 3.6, except for injection site swelling where a maximum size of up to 7 cm may occur in individual pigs. Injection site swellings are very commonly accompanied by redness and crusts and disappear within 6 weeks after vaccination. Lying down and malaise can be uncommonly observed in vaccinated pigs. Elevated temperatures (mean 0.3°C, individual pigs up to 1.2°C) may commonly occur on the day of vaccination. The animals return to normal 1 to 2 days after the peak temperature is observed. The product literature of Porcilis PCV ID, Porcilis M Hyo ID ONCE and Porcilis PRRS should be consulted.

Single-use safety and efficacy data are available in pigs from 3 weeks of age onwards which demonstrate that this vaccine can be mixed and administered with Porcilis PCV M Hyo ID and/or non-mixed with Porcilis PRRS. The administration site of non-mixed vaccines should be separated by approximately 3 cm. Adverse events are as described in section 3.6, except for injection site swellings with a maximum diameter of up to 15 cm in individual breeding pigs. Injection site swellings may show other signs of inflammation (pain, reddening, warmth and crusts). Elevated temperatures (mean 1.1°C, individual breeding pigs up to 2.4°C) may commonly occur on the day of vaccination. The product literature of Porcilis PCV M Hyo ID and Porcilis PRRS should be consulted before administration.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

3.9 Administration routes and dosage

Intradermal use.

Reconstitute the lyophilisate in the solvent or directly in Porcilis PCV ID or in Porcilis PCV M Hyo ID as follows:

Lyophilisate	Solvent for Porcilis Lawsonia ID, or Porcilis PCV ID or Porcilis PCV M Hyo ID
50 doses	10 ml
100 doses	20 ml

For proper reconstitution and correct administration, use the following procedure:

1. Allow the solvent, or Porcilis PCV ID or Porcilis PCV M Hyo ID to reach room temperature and shake well before use.
2. Add approximately 5-10 ml of the solvent, or Porcilis PCV ID or Porcilis PCV M Hyo ID to the lyophilisate vial and mix briefly.
3. Withdraw the reconstituted concentrate from the vial and transfer it back into the vial with the solvent or with Porcilis PCV ID or with Porcilis PCV M Hyo ID. Shake briefly to mix.
4. Use the vaccine suspension within 6 hours of reconstitution. Any vaccine remaining at the end of this time should be discarded.

Avoid introduction of a contamination by multiple broaching.

Dosage:

A single dose of 0.2 ml of reconstituted vaccine in pigs starting at 3 weeks of age.

Vaccinate pigs by the intradermal route using a multi-dose needle-free injection device for intradermal application of liquids suitable to deliver a “jet-stream” volume of vaccine (0.2ml ± 10%) through the epidermal layers of the skin.

Safety and efficacy of Porcilis Lawsonia ID have been demonstrated using the device IDAL.

Visual appearance after reconstitution: homogenous white to nearly white emulsion after shaking.

3.10 Symptoms of Overdose (and where applicable, emergency procedures and antidotes)

No adverse events other than the local reactions described in section 3.6 were observed after the administration of a double dose of Porcilis Lawsonia ID reconstituted in solvent.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Zero days.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QI09AB18.

The product stimulates the development of active immunity against *Lawsonia intracellularis* in pigs.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix the lyophilisate with any other veterinary medicinal product, except the recommended “Solvent for Porcilis Lawsonia ID” or except the vaccines mentioned in section 3.8.

5.2 Shelf life

Shelf-life of the lyophilisate as packaged for sale: 3 years.

Shelf-life of the solvent as packaged for sale: 3 years.

Shelf-life after reconstitution according to directions: 6 hours.

5.3 Special precautions for storage

Lyophilisate and solvent:

Store in a refrigerator (2°C – 8°C).

Do not freeze.

Protect from light.

5.4 Nature and composition of immediate packaging

Lyophilisate:

Hydrolytic glass Type I vial of 50 doses or 100 doses closed with halogenobutyl rubber stoppers and sealed with aluminium caps.

Solvent:

Hydrolytic glass Type I vial of 10 ml closed with nitril rubber stoppers and sealed with aluminium caps.

PET (polyethylene terephthalate) vials of 20 ml closed with nitril rubber stoppers and sealed with aluminium caps.

Presentations:

Cardboard box with 1 x 50 doses of lyophilisate and cardboard box with 1 x 10 ml solvent
Cardboard box with 10 x 50 doses of lyophilisate and cardboard box with 10 x 10 ml solvent

Cardboard box with 1 x 100 doses of lyophilisate and cardboard box with 1 x 20 ml solvent
Cardboard box with 10 x 100 doses of lyophilisate and cardboard box with 10 x 20 ml solvent

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal products or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet Ireland Limited

7. MARKETING AUTHORISATION NUMBER(S)

VPA10996/280/001

8. DATE OF FIRST AUTHORISATION

08/01/2021

9. DATE OF THE LAST REVISION OF THE SUMMARY OF PRODUCT CHARACTERISTICS

14/05/2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database

(<https://medicines.health.europa.eu/veterinary>)